Immunex Message Board - Msg: 16519643

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: eric ross who wrote (589)	10/17/2001 5:21:37 PM
From: Arthur Radley	Read Replies (1) of 656

AGreed! But from this release, the reference to growing revenue in 2002 by 70% is MORE than impressive. Immunex third-quarter profits rise 26 percent (UPDATE: adds CEO comments, details, stock price, byline, previous Seattle) By Deena Beasley LOS ANGELES, Oct 17 (Reuters) - Drugmaker Immunex Corp. (NasdaqNM:IMNX - news) said on Wednesday its third quarter profits rose 26 percent as sales of its flagship arthritis treatment Enbrel climbed 15 percent and reaffirmed its outlook that sales of the drug could rise up to 70 percent next year over 2001 levels. ADVERTISEMENT Sales of Enbrel will be capped this year at around $750 million because of limited manufacturing capacity, but are on track to rise to between $900 million and $1.3 billion in 2002, Immunex Chief Executive Ed Fritzky told Reuters

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next